期刊文献+

血浆利钠肽及其活化酶corin在慢性低氧性肺动脉高压患者中的变化及意义探讨

Changes and significances of natriuretic peptide and cardiac protease corin in patients with hypoxic pulmonary hypertension
原文传递
导出
摘要 目的:探讨corin与利钠肽在慢性低氧性肺动脉高压发生发展中的临床意义及其对病情的评估作用。方法:纳入慢性低氧性肺动脉高压患者158例,分为2个亚组:轻度肺动脉高压组118例(Ⅰa组)、中重度肺动脉高压组40例(Ⅰb组);健康对照组60例(Ⅱ组)。ELISA法检测3组患者血浆corin、心房利钠肽(ANP)、脑利钠肽(BNP)、ANP前体(pro-ANP)及BNP前体(pro-BNP)水平,心脏彩色多普勒超声测定肺动脉收缩压(SPAP),血气分析检测动脉血氧分压(PaO_2)。计算pro-ANP/ANP与pro-BNP/BNP比值。采用Spearman检验进行相关性分析。结果:Ⅰa组血浆corin表达水平显著高于Ⅱ组,Ⅰb组较Ⅱ组与Ⅰa组均显著下降(均P<0.01);Ⅰa组与Ⅰb组血浆ANP、pro-ANP、BNP及pro-BNP均明显高于Ⅱ组,且Ⅰb组显著高于Ⅰa组(均P<0.01);Ⅰa组pro-ANP/ANP与pro-BNP/BNP均较Ⅱ组显著降低,Ⅰb组较Ⅰa组显著升高(均P<0.01)。相关性分析显示:在Ⅰa组与Ⅰb组中,SPAP与pro-ANP、ANP、pro-BNP、BNP均存在正相关性;在Ⅰa组中,血浆corin与pro-ANP、ANP、pro-BNP、BNP均存在正相关性;而在Ⅰb组中,corin与pro-ANP、ANP、pro-BNP、BNP均存在负相关性。结论:corin与利钠肽及其前体在不同肺动脉高压阶段中表达异常,且二者表达水平具有相关性,提示corin介导利钠肽活化过程,从而参与慢性低氧性肺动脉高压的发生发展。 Objective:To explore the clinical significance of corin and natriuretic peptide in the occurrence and development of chronic hypoxic pulmonary hypertension(CHPH).Method:A total of 158 patients with CHPH were enrolled and divided into two subgroups:118 patients with mild CHPH were included into GroupⅠa,and 40 patients with moderate to severe CHPH were included into GroupⅠb.Other 60 healthy subjects were enrolled into GroupⅡ.Levels of plasma corin,atrial natriuretic peptide(ANP),brain natriuretic peptide(BNP),ANP precursor(pro-ANP)and BNP precursor(pro-BNP)were measured by ELISA.Pulmonary arterial systolic pressure(SPAP)was measured by color Doppler echocardiography,and arterial partial oxygen pressure(PaO2)was measured by blood gas analysis.The ratio of pro-ANP/ANP and proBNP/BNP were calculated.Correlation analysis was used by Spearman test.Result:The level of plasma corin in groupⅠa was significantly higher than that in groupⅡ,and was significantly lower in in groupⅠb than those in groupⅡand groupⅠa(all P<0.01).Levels of plasma ANP,pro-ANP,BNP and pro-BNP in groupⅠa and groupⅠb were significantly higher than those in groupⅡ,and were significantly higher in groupⅠb than those in groupⅠa(all P<0.01).pro-ANP/ANP and pro-BNP/BNP in groupⅠa were significantly lower than those in groupⅡ,and were significantly higher in groupⅠb than those in groupⅠa(all P<0.01).The correlation analysis showed that SPAP was positively correlated with pro-ANP,ANP,pro-BNP and BNP in groupⅠa and groupⅠb;Plasma corin was positively correlated with pro-ANP,ANP,pro-BNP and BNP in groupⅠa,but negatively correlated with pro-ANP,ANP,pro-BNP and BNP in groupⅠb.Conclusion:Corin and natriuretic peptide are abnormally expressed in different stages of pulmonary hypertension,and their expression levels are correlated,suggesting that corin mediates the activation of natriuretic peptideandparticipates in the occurrence and development of CHPH.
作者 徐平 罗华 宋卫东 XU Ping;LUO Hua;SONG Weidong(Department of Respiratory,Peking University Shenzhen Hospital,Shenzhen,518000,China;Intensive Care Unit,Peking University Shenzhen Hospital,Shenzhen,518000,China)
出处 《临床心血管病杂志》 CAS 北大核心 2019年第5期439-443,共5页 Journal of Clinical Cardiology
基金 广东省自然科学基金资助项目(No:2017A030313830) 深圳市卫计委课题资助项目(No:201501021)
关键词 CORIN 利钠肽 利钠肽前体 慢性低氧 肺动脉高压 corin natriuretic peptide pro-natriuretic peptide hypoxia pulmonary hypertension
  • 相关文献

参考文献2

二级参考文献29

  • 1SWEDBERG K,KOMAJDA M,BOHM M,et al.Ivabradine and outcomes in chronic heart failure(SHIFT):a randomised placebo-controlled study[J].Lancet,2010,376:875-885.
  • 2VITOVEC J,SPINAROVA L,SPINAR J.Effects of selective heart rate reduction with Ivabradine on left ventricular remodeling and health related quality of life:result frome the SHIFT sub-studies[J].Vnitr Lek,2012,58:612-617.
  • 3VAN ESCH J H,MOLTZER E,VAN VEGHEL R,et al.Beneficial cardiac effects of the rennin inhibitors aliskiren in spontaneously hypertensive rats[J].Hypertens,2010,28:2145-2155.
  • 4MCMURRAY J J,PACKER M,DESAI A S,et al.Angiotensin-neprilysin inhibition versus enalapril in heart failure[J].N Engl J Med,2014,371:993-1004.
  • 5MOE G W,EZEKOWITZ J A,O'MEARA E,et al.The 2014Canadian Cardiovascular Society Heart Failure Management Guidelines Focus Update:anemia,biomarkers,and recent therapeutic trial implications[J].Can J Cardiol,2015,31:3-16.
  • 6PITT B,ZANNAD F,REMME W J,et al.The effect of spironolactone on morbidity and mortality in patients with severe heart failure.Randomized Aldactone Evaluation Study Investigators[J].N Engl JMed,1999,341:709-717.
  • 7ROSSIGNOL P,DOBRE D,MCMURRAY J J,et al.Incidence,determinants,and prognostic significance of hyperkalemia and worsening renal function in patients with heart failure receiving the mineralocorticoid receptor antagonist eplerenone or placebo in addition to optimal medical therapy:results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure(EMPHASIS-HF)[J].Circ Heart Fail,2014,7:51-58.
  • 8PITT B,REMME W,ZANNAD F,et al.Eplerenone,a selective aldosterone blocker,in patients with left ventricular dysfunction after myocardial infarction[J].N Engl J Med,2003,348:1309-1321.
  • 9PONIKOWSKI P,VAN VELDHUISEN D J,COM-IN-COLET J,et al Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency[J].Eur Heart J,2015,36:657-668.
  • 10GHEORGHIADE M,KONSTAM M A,BURNETTJ C JR,et al.Short-term clinical effects of tolvaptan,an oral vasopressin antagonist,in patients hospitalized for heart failure:the EVEREST Clinical Status Trials[J].JAMA,2007,297:1332-1343.

共引文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部